MedPath

Evaluate the Safety of GABITRIL in Adults With Generalized Anxiety Disorder

Phase 3
Completed
Conditions
General Anxiety Disorder
Registration Number
NCT00233675
Lead Sponsor
Cephalon
Brief Summary

To assess the long-term safety and tolerability of tiagabine treatment in patients with generalized anxiety disorder (GAD).

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
Not specified
Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (26)

Pivotal Research Center

πŸ‡ΊπŸ‡Έ

Mesa, Arizona, United States

Southwestern Research

πŸ‡ΊπŸ‡Έ

Beverly Hills, California, United States

Pharmacology Research Institut

πŸ‡ΊπŸ‡Έ

Northridge, California, United States

Pacific Clinical Research Medi

πŸ‡ΊπŸ‡Έ

Orange, California, United States

Radiant Research San Diego

πŸ‡ΊπŸ‡Έ

San Diego, California, United States

Affiliated Research Institute

πŸ‡ΊπŸ‡Έ

San Diego, California, United States

Radiant Research Denver

πŸ‡ΊπŸ‡Έ

Denver, Colorado, United States

University of Connecticut

πŸ‡ΊπŸ‡Έ

Farmington, Connecticut, United States

Clinical Neuroscience Solution

πŸ‡ΊπŸ‡Έ

West Palm Beach, Florida, United States

Carman Research

πŸ‡ΊπŸ‡Έ

Smyrna, Georgia, United States

Scroll for more (16 remaining)
Pivotal Research Center
πŸ‡ΊπŸ‡ΈMesa, Arizona, United States

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

Β© 2025 MedPath, Inc. All rights reserved.